Ironwood Pharmaceuticals Inc (IRWD) · Nov 5, 2026 · Earnings
Ironwood earnings beat as LINZESS rebound drives second guidance raise
Beat — Diluted EPS $0.36 vs ~$0.32 consensus; revenue $133.0M vs ~$120.0M
Ironwood’s third-quarter earnings beat consensus while LINZESS growth drove a second consecutive 2026 guidance raise across sales, revenue and EBITDA.
Ironwood is rebuilding around a stronger LINZESS franchise while funding apraglutide’s confirmatory STARS-2 trial. The prior story already included improving LINZESS pricing and demand, a recently initiated Phase 3 program, and an August guidance increase; this filing shows that momentum is translating into results rather than merely remaining a forecast.
The quarter beat a modest published bar. Third-quarter revenue reached $133.0 million versus roughly $120.0 million expected, while diluted EPS was $0.36 versus approximately $0.32 consensus. That is a genuine earnings beat, not just year-over-year improvement: revenue rose 9.0% from $122.1 million and diluted EPS rose from $0.23. (Income Statement) The operating result was also cleaner, with quarterly adjusted EBITDA of $97.9 million versus $81.8 million a year ago. (Adjusted EBITDA reconciliation)
| Q3 2026 | Q3 2025 | Consensus |
|---|
| Total revenue (Income Statement) | $133.0M (+9.0%) | $122.1M | ~$120.0M |
| Diluted EPS (Income Statement) | $0.36 (+$0.13) | $0.23 | ~$0.32 |
| Adjusted EBITDA (Adjusted EBITDA reconciliation) | $97.9M (+19.7%) | $81.8M | |
| LINZESS U.S. net sales (LINZESS collaboration table) | $324.9M (+3.2%) | $314.9M | |
| Commercial margin (LINZESS collaboration table) | 80% (+4 pts) | 76% | |
The bigger signal is the second consecutive guidance raise. Ironwood lifted full-year LINZESS U.S. sales to $1.20–$1.25 billion from $1.15–$1.20 billion, total revenue to $485–$510 million from $460–$485 million, and adjusted EBITDA to above $350 million from above $310 million. (2026 Guidance) The midpoint increases are about 4% for LINZESS and 5% for total revenue, while the EBITDA floor rises by more than 13%; that suggests both demand and operating leverage are contributing. The market already knew the recovery was underway, so the surprise is the durability and magnitude of the follow-through.
LINZESS is doing more than growing sales—it is improving the economics of the core business. Nine-month U.S. LINZESS sales reported by AbbVie reached $879.8 million, up from $701.3 million, while Ironwood’s U.S. collaborative-arrangements revenue rose to $344.2 million from $244.1 million. (LINZESS collaboration tables) Commercial margin expanded to 78% from 69%, and Ironwood’s share of net profit increased to $343.2 million from $240.9 million. (LINZESS collaboration table) That supports the company’s claim that improved net pricing and prescription growth are restoring LINZESS as a stronger profit engine, rather than growth being purchased through heavier spending. 〔0〕
The balance sheet is improved from year-end but still limits the story’s quality. Cash fell to $86.4 million from $215.5 million, while the revolving credit facility stood at $325.0 million versus $385.0 million at December 31, 2025. (Balance Sheet) The lower debt reflects the earlier convertible-note repayment and ongoing debt reduction, but total liabilities still exceeded assets and stockholders’ deficit remained $97.2 million. (Balance Sheet) This does not negate the operating beat, but it means the stronger cash generation is also needed to repair financial flexibility while STARS-2 advances.
Apraglutide remains an execution story, not a new clinical result. The filing says STARS-2 is ramping up, with U.S. sites being added and international clinical trial applications submitted or already approved, but it provides no enrollment count, efficacy readout, or regulatory milestone. 〔1〕 The program advances operationally, but the quarter’s measurable value comes from LINZESS and profitability rather than new clinical evidence.
Bottom line: This is a clear execution beat with a meaningful second guidance raise, strengthening Ironwood’s near-term operating story. It does not rewrite the longer-term pipeline case, but it shows LINZESS recovery and margin expansion are arriving faster and more profitably than expected.
What to watch next
STARS-2 enrollment and international site activation updates
Original filing on SEC EDGAR
More Ironwood Pharmaceuticals Inc news
